Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-450-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$570,000.00
Profitability
Miscellaneous
Employees147
OptionableOptionable
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its quarterly earnings results on Thursday, August, 2nd. The specialty pharmaceutical company reported ($1.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.41) by $0.15. The specialty pharmaceutical company had revenue of $7.57 million for the quarter, compared to the consensus estimate of $4.84 million. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. View Adamas Pharmaceuticals' Earnings History.
When is Adamas Pharmaceuticals' next earnings date?
What price target have analysts set for ADMS?
9 brokers have issued 1-year target prices for Adamas Pharmaceuticals' stock. Their predictions range from $11.00 to $49.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $30.7143 in the next twelve months. This suggests a possible upside of 193.6% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.
What is the consensus analysts' recommendation for Adamas Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (2/13/2019)
- 2. Mizuho analysts commented, "We see minimal 2019 catalysts or take-out possibility for Adamas, and reiterate our Neutral rating. We also believe the stock will be pressured by the recent launch of Osmolex ER. We updated our model following guidance on 2019 Gocovri growth and a 7.75% price increase, with no change to our $11 PT." (1/11/2019)
- 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation ascribes a $1.15B valuation to GOCOVRI in PD $400M value for ADS-5102 based on a risk-adjusted net present value (rNPV) that employs a 15% discount rate, 30% effective tax rate and 30% cost of sales and marketing. We utilize a 60% probability of success for ADS-5102." (11/5/2018)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
News headlines about ADMS stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Retrophin (RTRX) and CannTrust (CNTTF).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
- Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
- Ashleigh Barreto, Director of Corp. Communications & Investor Relations
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (9.91%), Broadfin Capital LLC (9.56%), BlackRock Inc. (7.55%), Sectoral Asset Management Inc (4.15%), Emerald Advisers LLC (2.38%) and Emerald Mutual Fund Advisers Trust (2.07%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni, Richard King and William J Dawson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Which major investors are selling Adamas Pharmaceuticals stock?
ADMS stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Bank of New York Mellon Corp, Deltec Asset Management LLC, Granite Point Capital Management L.P., Rhenman & Partners Asset Management AB, Emerald Mutual Fund Advisers Trust, Squarepoint Ops LLC and Bainco International Investors. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Insider Buying and Selling for Adamas Pharmaceuticals.
Which major investors are buying Adamas Pharmaceuticals stock?
ADMS stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Macquarie Group Ltd., Sectoral Asset Management Inc, Millennium Management LLC, BlackRock Inc., Fosun International Ltd, Bank of America Corp DE and Two Sigma Investments LP. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $10.46.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $285.93 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
What is Adamas Pharmaceuticals' official website?
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
